New blood product tested for safer liver transplants
NCT ID NCT07265843
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This study tests two blood products used to control bleeding during liver transplant surgery. It compares a newer product, Intercept Fibrinogen Complex, to standard cryoprecipitate. The goal is to see if the newer product works as well or better at stopping bleeding. The study will involve 60 adults scheduled for a liver transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Cincinnati
Cincinnati, Ohio, 45221, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Intercept Fibrinogen Complex (IFC) and Cryoprecipitate Antihemophilic Factor (AHF)
What this could lead to
If successful, this could show that the newer blood product is a safe and effective option for controlling bleeding during liver transplant, potentially improving access and outcomes.
What could go wrong
This is a small, early pilot study with only 60 participants, so results may not apply to all patients. There is also a risk of allergic reactions or other complications from blood products.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.